Viatris (VTRS)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$16.88-0.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Intact: The reason to own it still holds.
Viatris aims for about $14.7B revenue in 2026. Free cash flow should reach $2.15B. New products brought $71M revenue in Q1. The company is cutting costs to improve profits.
Revenue growth is slow and guidance was cut recently. The company is still loss making. Cost cuts may not be enough to fix problems.
The price is about 20% below our fair value near $21. Analysts expect about 2% revenue growth. We see risk from recent guidance cuts and cost issues.
Breaks if: Cost savings do not materialize or reverse in 2026
Breaks if: Free cash flow falls below $2.0B in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on cost savings and product launches. The current thesis state indicates that while recent financial performance has been strong, the company remains volatile and loss-making.
The market appears to have priced in a level of fragility, as indicated by a low expectations gap. VTRS is viewed as cheap compared to peers, suggesting that investors may expect some recovery or improvement in fundamentals.
Management is on track with its cost-saving initiatives and has recently raised financial guidance, reflecting confidence in future performance. However, the company operates in a high-miss-rate industry, which introduces some near-term risk despite a low probability of missing expectations.
The long-term thesis hinges on the successful execution of management's strategic priorities, including cost savings and product launches. Additionally, the performance of sector bellwethers and overall economic conditions will be critical in shaping the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Viatris reaffirms its 2026 financial guidance, maintaining revenue and cash flow targets.
Breaks if: New product revenue fails to grow beyond $71M in Q1 run rate
Breaks if: Revenue falls below $13.9B in FY26
Viatris reaffirms its 2026 financial guidance, maintaining revenue and cash flow targets.
In the next 1 to 3 years, VTRS's performance will depend on its ability to navigate execution risks while capitalizing on sector momentum. Not investment advice.